Shenzhen Kangtai Biological Products Co., Ltd.
Symbool: 300601.SZ
SHZ
22.57
CNYMarktprijs vandaag
33.5591
Koers/Winst Verhouding
0.2598
Koers/Winst Groei Verhouding
24.02B
MRK Kapitalisatie
- 0.01%
DIV Rendement
Shenzhen Kangtai Biological Products Co., Ltd. (300601-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1758.9 | 1458.4 | 3549.5 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 563.4 | 440.8 | 725.6 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 2819.2 | 2414.7 | 1991.2 | ||||||||||||
balance-sheet.row.inventory | 0 | 772.9 | 727.8 | 1058.2 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 45 | 573.9 | 741.7 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 5396 | 5174.9 | 7340.7 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 5756.9 | 5176.1 | 4116.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 2696.2 | 2041.3 | 99.4 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 630.3 | 708.3 | 558.6 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 101.7 | 210.6 | 1297.6 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 9689.4 | 8611.5 | 6808.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.account-payables | 0 | 791.2 | 434.1 | 708.2 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 174.3 | 273.7 | 800.1 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 25.9 | 173.4 | 98.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 2372.2 | 2015.7 | 1938 | ||||||||||||
Deferred Revenue Non Current | 0 | 328.7 | 383.1 | 349.5 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 1757.1 | 1600.8 | 2.8 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2463.6 | 2461.2 | 2364.1 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-liab | 0 | 5215 | 4801 | 4982.2 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 1116.9 | 1120.5 | 687.1 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 2216.7 | 1641.1 | 2435 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 3117.4 | 3036 | 2417.5 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 3090.6 | 3187.7 | 3627.1 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 0 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 3259.6 | 440.8 | 99.4 | ||||||||||||
balance-sheet.row.total-debt | 0 | 2546.6 | 2289.4 | 2738.1 | ||||||||||||
balance-sheet.row.net-debt | 0 | 1351 | 1271.7 | -811.4 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -132.7 | 1263.4 | 679.2 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 200.9 | 404.7 | 92.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 10 | 30 | 104.8 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | -604.5 | -275.6 | -461.7 | |||||||||||
cash-flows.row.account-receivables | 0 | -488.8 | 273.9 | -796.5 | |||||||||||
cash-flows.row.inventory | 0 | 220.7 | -746.7 | -209.7 | |||||||||||
cash-flows.row.account-payables | 0 | -131 | 146.5 | 451.3 | |||||||||||
cash-flows.row.other-working-capital | 0 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 1277.6 | 179.2 | -68.6 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0.1 | 0.2 | 1227.7 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -3518 | -1100 | -2625 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2224.4 | 2198.2 | 13.7 | |||||||||||
cash-flows.row.other-investing-activites | 0 | -2.4 | 1.7 | -1226.7 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -2606.3 | -1440.3 | -3836.9 | |||||||||||
cash-flows.row.debt-repayment | 0 | -1070.4 | -26.5 | -256 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 132.7 | -2.1 | -1 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | -20.6 | 2.1 | -0.2 | |||||||||||
cash-flows.row.dividends-paid | 0 | -622.2 | -220.4 | -207.3 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 1115.6 | 2699 | 4243.3 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -464.9 | 2452.2 | 3778.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -1.7 | -1 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | -2527.1 | 2663.1 | 381.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 994.1 | 3521.3 | 858.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3521.3 | 858.1 | 476.5 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 545.7 | 1652.3 | 439.8 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.free-cash-flow | 0 | -764.7 | -888.1 | -786.8 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 3451.8 | 3157.4 | 3652.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 622.8 | 499.9 | 986.4 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 2829.1 | 2657.5 | 2665.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 2054.2 | 2020.8 | 1071.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 2677 | 2520.8 | 2058.4 | ||||||||||||
income-statement-row.row.interest-income | 0 | 115.6 | 132.6 | 114.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 240.7 | 200.9 | 676.6 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | 774.8 | 747 | 1452.2 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | 940.3 | -338.2 | 1439.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 79 | -205.5 | 175.9 | ||||||||||||
income-statement-row.row.net-income | 0 | 861.3 | -132.7 | 1263.4 |
Vaak gestelde vragen
Wat is Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) totale activa?
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) totale activa is 15085358535.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.832.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.224.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.213.
Wat is Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) nettowinst (netto-inkomen)?
De nettowinst is 861303903.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 2546554090.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 2054244031.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.